Global Doxorubicin Market Research Report (2021-2027)


Global Doxorubicin Market

Global Doxorubicin Market

Global Doxorubicin Market

Dublin, 02 Feb. 2022 (GLOBE NEWSWIRE) — The report “Doxorubicin Market Research Report by Drug Formulation, by Application, by Distribution Channel, by Region – Global Forecast to 2027 – Cumulative Impact of COVID-19” has been added to the report. from offer.

The global Doxorubicin market size was estimated at USD 1,777.09 million in 2020, is projected to reach USD 1,959.95 million in 2021, and is projected to grow at a CAGR of 10.65% to reach USD 3,610.21 million by 2027.

Market statistics:

The report provides market size analysis and forecasts for five major currencies – USD, EUR GBP, JPY and AUD. It helps organizational leaders make better decisions when currency data is readily available. In this report, the years 2018 and 2019 are considered as historical years, 2020 as the base year, 2021 as the estimated year and the years from 2022 to 2027 as the forecast period.

Segmentation and market coverage:

This research report categorizes Doxorubicin to forecast revenues and analyze trends in each of the following submarkets:

  • Based on the drug formulation market studied through Doxorubicin Injection and Lyophilized Powder.

  • Based on the application, the market has been studied on bone sarcoma, breast cancer, endometrial cancer, gastric cancer, Kaposi’s sarcoma, kidney cancer, leukemia, cancer of the liver, multiple myeloma and ovarian cancer.

  • Based on distribution channel, the market has been studied in hospital pharmacy, online pharmacy, and retail pharmacy.

  • Based on region, the market has been studied in Americas, Asia-Pacific and Europe, Middle East & Africa. The Americas are studied in more detail through Argentina, Brazil, Canada, Mexico and the United States. The United States is studied in more detail through California, Florida, Illinois, New York, Ohio, Pennsylvania and Texas. Asia-Pacific is studied in more detail across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan and Thailand. Europe, the Middle East and Africa are studied in more detail in France, Germany, Italy, the Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, the United Arab Emirates and the United Kingdom.

Competitive Strategy Window:

The strategic competitive window analyzes the competitive landscape in terms of markets, applications and geographies to help the vendor define an alignment or match between its capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for vendors to adopt successive strategies of merger and acquisition, geographic expansion, research and development, and new product introduction strategies to execute further business expansion and growth. during a forecast period.

FPNV positioning matrix:

The FPNV Positioning Matrix evaluates and ranks vendors in the Doxorubicin Market based on business strategy (business growth, industry coverage, financial viability, and channel support) and product satisfaction (ratio price-performance, ease of use, product features and customer support) that helps businesses make better decisions and understand the competitive landscape.

Market share analysis:

The market share analysis offers the analysis of the vendors considering their contribution to the overall market. It gives the idea of ​​its revenue generation in the overall market compared to other providers in the space. It provides information on the performance of vendors in terms of revenue generation and customer base compared to others. Knowing the market share gives an idea of ​​the size and competitiveness of suppliers for the reference year. It reveals the characteristics of the market in terms of accumulation, fragmentation, dominance and merger.

Enterprise Usability Profiles:

The report thoroughly explores recent significant developments by leading vendors and innovation profiles in the global Doxorubicin market including Accord Healthcare, Allergan, Inc., Cadila Pharmaceuticals, Changzhou Kinyond Pharmaceutical Co., Ltd, Cipla, Inc., Dr. Reddy’s Laboratories Ltd., Getwell Oncology Pvt Ltd., Glenmark Pharmaceuticals Ltd., Janssen Products, LP, Johnson & Johnson, LGM Pharma, Manus Aktteva Biopharma LLP, Meiji Holdings Co., Ltd., Merrimack Pharmaceuticals, Inc., Novartis AG , Pfizer, Inc. ., SRS Pharmaceuticals Pvt. Ltd., Sun Pharmaceutical Industries Ltd., Teva Pharmaceuticals, Thymoorgan Pharmazie GmbH and TTY Biopharma.

The report provides information about the following pointers:
1. Market Penetration: Provides comprehensive information about the market offered by major players
2. Market Development: Provides detailed information on lucrative emerging markets and analyzes penetration in mature market segments
3. Market Diversification: Provides detailed information on new product launches, untapped geographies, recent developments and investments
4. Competitive Assessment and Intelligence: Provides a comprehensive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of key players
5. Product Development and Innovation: Provides smart insights into future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:
1. What is the market size and forecast of the global Doxorubicin market?
2. What are the inhibiting factors and impact of COVID-19 on the global doxorubicin market during the forecast period?
3. What are the products/segments/applications/areas to invest in during the forecast period in the global Doxorubicin market?
4. What is the competitive strategic window for opportunities in the Global Doxorubicin Market?
5. What are the technological trends and regulatory frameworks in the global doxorubicin market?
6. What is the market share of the major vendors in the global doxorubicin market?
7. What modes and strategic moves are considered suitable for entering the Global Doxorubicin Market?

Main topics covered:

1. Preface

2. Research methodology

3. Executive Summary

4. Market Overview

5. Market Overview
5.1. Market dynamics
5.1.1. Drivers Increase government support for technological advances in clinical oncology Increase in cancer incidence rate Increasing use in the treatment of AIDS-related malignancies of the breast, Kaposi’s sarcoma, multiple myeloma and acute meroblastic leukemia
5.1.2. Constraints Drug side effects and life-threatening conditions such as heart failure during or after treatment
5.1.3. Opportunities The growing burden of cancer in Asian economies Growing effort to increase awareness and availability of medicines
5.1.4. Challenges Gap between supply and demand in some regions of the world
5.2. Cumulative impact of COVID-19

6. Doxorubicin Market, By Drug Formulation
6.1. introduction
6.2. Doxorubicin injection
6.3. Freeze-dried powder

7. Doxorubicin Market, By Application
7.1. introduction
7.2. Bone sarcoma
7.3. Breast cancer
7.4. endometrial cancer
7.5. Stomach cancer
7.6. Kaposi’s sarcoma
7.7. kidney cancer
7.8. Leukemia
7.9. Liver cancer
7.10. Multiple myeloma
7.11. Ovarian cancer

8. Doxorubicin Market, By Distribution Channel
8.1. introduction
8.2. Hospital pharmacy
8.3. Online pharmacy
8.4. Retail pharmacy

9. Americas Doxorubicin Market
9.1. introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States

10. Asia Pacific Doxorubicin Market
10.1. introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand

11. Europe, Middle East and Africa Doxorubicin Market
11.1. introduction
11.2. France
11.3. Germany
11.4. Italy
11.5. Netherlands
11.6. Qatar
11.7. Russia
11.8. Saudi Arabia
11.9. South Africa
11.10. Spain
11.11. United Arab Emirates
11.12. UK

12. Competitive landscape
12.1. FPNV positioning matrix
12.1.1. Quadrants
12.1.2. Business strategy
12.1.3. Product Satisfaction
12.2. Market Ranking Analysis
12.3. Market share analysis, by key player
12.4. Competitive scenario
12.4.1. Merger & Acquisition
12.4.2. Agreement, collaboration and partnership
12.4.3. Launching and improving new products
12.4.4. Investment & Financing
12.4.5. Reward, recognition and expansion

13. Enterprise Usability Profiles
13.1. Health Agreement
13.2. Allergan, Inc.
13.3. Cadila Pharmaceuticals
13.4. Changzhou Kinyond Pharmaceutical Co.,Ltd
13.5. Cipla, Inc.
13.6. Dr. Reddy’s Laboratories Ltd.
13.7. Getwell Oncology Pvt Ltd
13.8. Glenmark Pharmaceuticals Ltd.
13.9. Janssen Products, LP
13.10. Johnson & Johnson
13.11. LGM Pharma
13.12. Manus Aktteva Biopharma LLP
13.13. Meiji Holdings Co., Ltd.
13.14. Merrimack Pharmaceuticals, Inc.
13.15. Novartis AG
13.16. Pfizer, Inc.
13.17. SRS Pharmaceuticals Pvt. ltd.
13.18. Sun Pharmaceutical Industries Ltd.
13.19. Teva Pharmaceuticals
13.20. Thymoorgan Pharmazie GmbH
13.21. biopharmaceutical ATS

14. Appendix

For more information about this report visit


CONTACT: CONTACT: Laura Wood, Senior Press Manager [email protected] For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

Comments are closed.